Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma

The farnesyl transferase inhibitor (FTI) SCH66336 has been shown to have antitumor activities in head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. However, its mechanism of action has not been well defined. Here, we report that the insulin-like growth factor (IGF) binding protein (IGFBP)-3 mediates antitumor activities of SCH66336 in HNSCC by inhibiting angiogenesis. SCH66336 significantly suppressed HNSCC tumor growth and angiogenesis via mechanisms that are independent of H-Ras and RhoB. By inducing IGFBP-3 secretion from HNSCC cells, this compound suppresses angiogenic activities of endothelial cells, including vessel formation in chorioallantoic membranes of chick, endothelial cell sprouting from chick aorta, and capillary tube formation of human umbilical vascular endothelial cells (HUVEC). Knockdown of IGFBP-3 expression in HNSCC cells by RNA interference or depletion of IGFBP-3 in HUVECs by neutralizing antibody effectively blocked the effects of IGFBP-3 secreted from SCH66336-treated HNSCC cells on HUVECs. These findings suggest that IGFBP-3 could be a primary target for antitumor activities of FTIs and that IGFBP-3 is an effective therapeutic approach against angiogenesis in HNSCC.

[1]  Edward S. Kim,et al.  Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. , 2005, Journal of the National Cancer Institute.

[2]  F. Khuri,et al.  Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer , 2004, Oncogene.

[3]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.

[4]  M. Spitz,et al.  Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer , 2004, Clinical Cancer Research.

[5]  A. Ardizzoni,et al.  In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. , 2004, Oncology reports.

[6]  Y. Gho,et al.  Capsaicin Inhibits in Vitro and in Vivo Angiogenesis , 2004, Cancer Research.

[7]  N. Mitsiades,et al.  0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(11):5392–5398 Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/jc.2003-030389 Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like G , 2022 .

[8]  P. Cohen,et al.  Epidemiology and Biology of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) as an Anti-cancer Molecule , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[9]  F. Khuri,et al.  Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. , 2003, Cancer research.

[10]  R. Lotan,et al.  Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. , 2003, Journal of the National Cancer Institute.

[11]  D. Alkon,et al.  Secretion of Annexin II via Activation of Insulin Receptor and Insulin-like Growth Factor Receptor* , 2003, The Journal of Biological Chemistry.

[12]  P. Cohen,et al.  Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. , 2003, The Journal of clinical endocrinology and metabolism.

[13]  C. Mantzoros,et al.  The Role of the IGF System in Cancer: From Basic to Clinical Studies and Clinical Applications , 2002, Oncology.

[14]  G. Daley,et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. , 2002, Blood.

[15]  Pinchas Cohen,et al.  Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. , 2002, Cancer research.

[16]  M. Rechler,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[17]  R. Weber,et al.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  R. Kalluri,et al.  Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. , 2002, Cancer research.

[19]  J. Karp,et al.  Current status of clinical trials of farnesyltransferase inhibitors , 2001, Current opinion in oncology.

[20]  G E Walker,et al.  Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. , 2001, Endocrinology.

[21]  A. Guha,et al.  Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. , 2001, Cancer research.

[22]  J. Karp,et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.

[23]  R. Baxter.  Signalling pathways involved in antiproliferative effects of IGFBP-3: a review , 2001, Molecular pathology : MP.

[24]  S. Sebti,et al.  The Farnesyltransferase Inhibitor, FTI-2153, Blocks Bipolar Spindle Formation and Chromosome Alignment and Causes Prometaphase Accumulation during Mitosis of Human Lung Cancer Cells* , 2001, The Journal of Biological Chemistry.

[25]  T. Jessell,et al.  RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors , 2000, Molecular and Cellular Biology.

[26]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[27]  Walter A. Korfmacher,et al.  Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. , 1998, Cancer research.

[28]  P. Brodt,et al.  Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. , 1998, Cancer research.

[29]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[30]  S. Leal,et al.  The Type V Transforming Growth Factor β Receptor Is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor* , 1997, The Journal of Biological Chemistry.

[31]  J. Horiot,et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  M. Binoux,et al.  The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. , 1997, Endocrinology.

[33]  P. Casey,et al.  Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB* , 1997, The Journal of Biological Chemistry.

[34]  S. Armstrong,et al.  CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoB (*) , 1995, The Journal of Biological Chemistry.

[35]  P. Cohen,et al.  The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. , 1995, Molecular endocrinology.

[36]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[37]  D. Clemmons,et al.  Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs. , 1992, Endocrinology.

[38]  W. Blot,et al.  Second primary tumors in patients with oral cancer , 1992, Cancer.

[39]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. , 1990, Cancer research.

[40]  I. Fidler,et al.  An orthotopic nude mouse model of oral tongue squamous cell carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[42]  W. R. Bishop,et al.  The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines. , 2001, Experimental cell research.

[43]  G. Devi,et al.  Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. , 2000, Endocrinology.

[44]  W. R. Bishop,et al.  The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo , 2000, Cancer Chemotherapy and Pharmacology.

[45]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[46]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.